Adalimumab – March 2026

Injection 20 mg in 0.2 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled pen, Injection 80 mg in 0.8 mL pre-filled pen, ,

  • Brand names:
    • Amgevita®
  • Pharmaceutical Company:
    • AMGEN AUSTRALIA PTY LIMITED
  • Condition/Indication: Crohn disease. Ulcerative colitis. Active juvenile idiopathic arthritis. Complex refractory fistulising Crohn disease. Active rheumatoid arthritis. Psoriatic arthritis. Ankylosing spondylitis. Chronic plaque psoriasis. Hidradenitis suppurativa
  • Meeting Date: March 2026
Public Summary Documents
Last updated
11 March 2026